Agno Pharma has acquired Actylis Eugene, the legacy Cascade Chemistry business based in Eugene, Oregon.

With over 20 years, the Eugene site brings a legacy in small-molecule Active Pharmaceutical Ingredient (API) development and manufacturing, anchored by a 16,000 square-foot R&D lab facility as well as a newly constructed 30,000 square-foot manufacturing facility, equipped with state-of-the-art Good Manufacturing Practice (GMP) infrastructure supporting early-phase to late-phase clinical API production. Under Actylis, the Eugene site received significant investment to expand and upgrade its GMP manufacturing operations, and represents a robust platform well positioned for future growth.

“We would like to thank Actylis for its investments and stewardship of the Eugene site, and we are extremely excited to welcome the Eugene team into the Agno Pharma platform. This acquisition is a transformative step forward in building a differentiated development and manufacturing hub. The Eugene site brings technical depth in early-phase API development and its high-quality GMP infrastructure will be a powerful driver of new business as we support innovative biotech and pharmaceutical partners developing novel chemical entities,” said James Chen, PhD, Chief Executive Officer, Agno Pharma.

Today, Agno Pharma already serves a global client-base including blue-chip pharmaceutical and biotech companies, supplying critical GMP intermediates and APIs, drug product and drug implant formulation services, as well as analytical services from pre-clinical through commercial phases. The acquisition of the Eugene asset meaningfully expands Agno’s manufacturing footprint and reinforces its commitment to serve its customers with onshore pharmaceutical manufacturing in the US.

Following the transaction, Agno plans to execute a disciplined and seamless integration, maintaining uninterrupted service for existing customers and accelerating investment in the site to enhance capabilities and drive long-term growth.